Inventurus Knowledge Solutions Ltd(IKS)

NSE: IKSBSE: 544309

₹ 1,620.15-1.47%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 27,797 crWebsite: www.ikshealth.comUpdated: 24 Oct 2026

About

Inventurus Knowledge Solutions (IKS) is an IT-enabled services company providing outsourced clinical, revenue cycle, and practice management solutions exclusively to US healthcare providers. In FY26, IKS reported revenue of INR 3,193 crores, growing ~20% year-on-year. The company serves approximately 18% of all US physicians across 700+ clients, and in July 2026 closed the acquisition of TruBridge - a rural hospital EHR and RCM platform - creating a combined business with an annualised revenue run-rate of ~$688 million.^[1][2][3][4]

Services portfolio

IKS offers a multi-feature Care Enablement Platform covering revenue cycle management (RCM), autonomous medical coding, ambient clinical documentation (Scribble), patient financial clearance, prior authorisation, and value-based care support for physician enterprises.^[5][6]
TruBridge (acquired July 10, 2026) adds an EHR system-of-record and separate RCM services for rural/community US hospitals; TTM 2025 revenue split: ~$126mn EHR, ~$221mn RCM.^[4]
Scribble Select, a multi-variant ambient scribing product with an optional human-in-the-loop, was launched in Q4 FY26; MyCare Hub, a multi-agent patient engagement product, was also launched in Q4 FY26.^[4]
IKS launched the industry's first connected encounter-to-reimbursement agentic platform on Google Cloud in Q2 FY26, handling ~80% of tasks autonomously across documentation, coding and RCM workflows.^[5]
As of Q4 FY26, seven IKS features are listed in the Epic Connection Hub / App Showroom, including autonomous coding, MyCare Hub, Scribble, and Stacks, giving distribution access into the ~75 - 80% of large US health systems that run Epic.^[4][5]

Key operating numbers

Q1 FY27 USD revenue: $97mn, +12% year-on-year in constant currency; INR revenue INR 8,936mn, +20.7% year-on-year.^[3]
Headcount grew only 4.2% year-on-year (12,300 in June 2025 to 12,889 in June 2026) against 12% constant-currency revenue growth, continuing the non-linear operating model.^[3]
Q1 FY27 reported EBITDA margin: 33.0%; adjusted for ~INR 20cr one-time TruBridge acquisition costs, adjusted EBITDA was ~INR 314cr at ~35%, consistent with Q4 FY26 operating levels.^[3]
FY26 full-year EBITDA: INR 1,091 crores (+38% year-on-year); OCF/EBITDA improved from 55% in FY25 to 79% in FY26; FCF/PAT improved from 56% to 85%.^[4]
Top-5 customers contributed 42.1% of Q1 FY27 revenue (INR 3,759mn); top-10 customers contributed 53.8% (INR 4,808mn); average vintage of top-10 clients exceeds six years.^[3]
R&D spend was ~4.7% of revenue in Q3 FY26, up from ~3.86% in Q2 FY25, reflecting increasing investment in proprietary AI products.^[6][5]

Customers and distribution

IKS serves ~18% of all US physicians across 700+ clients as of FY25, with a stated strategic focus exclusively on the US healthcare provider market.^[2][5]
Advocate Health - a top-5 US health system with over $35bn in annual revenue - significantly expanded its RCM and coding partnership with IKS in Q1 FY27.^[3]
In Q3 FY26, IKS signed platform deals with VitalMD/Femwell Group (800+ providers, Scribble ambient AI) and StrideCare (full RCM + coding), both ramping from Q1 FY27.^[6]
In Q2 FY26, new full-platform wins included Revere Health (largest independent physician group in Utah), Jackson Clinic (Tennessee multi-specialty), and a national cardiology roll-up.^[5]
TruBridge holds 700+ rural hospital EHR clients and an estimated 40%+ market share in the 0 - 50 bed US hospital segment.^[4]

Operations and workforce

Global headcount was 12,889 as of June 30, 2026 (Q1 FY27), down from a peak of ~13,350 in Q3 FY26, reflecting AI-driven workforce productivity gains. Gender diversity ratio was 51% as of March 31, 2025.^[3][6][2]
IKS received KLAS Best in KLAS 2026 for Virtual Scribing Services (score 91.9/100) for the second consecutive time, and was rated #1 in AI-driven RCM and Medical Coding and #1 in Clinical Documentation by KLAS and Blackbook.^[6]
The Palomar Health outcome-aligned deal (NEVA model) generated $3mn of net economic value add in the first four months of full go-live against a $16.5mn upfront advance, validating the performance-based commercial model.^[6]

Acquisition: TruBridge

IKS acquired TruBridge (NASDAQ-listed) for $557mn enterprise value ($427mn equity + $130mn assumed debt), funded by ~$600mn 5-year term debt at SOFR+275bps; deal closed July 10, 2026.^[4][3]
TruBridge's annualised revenue base at close was reset to ~$300mn (from $340mn anticipated pre-close), due to conservative revenue-recognition adjustment (~$2 - 3mn/quarter), elimination of two unprofitable service lines (~$8mn/quarter), and customer discounts (~$2 - 3mn/quarter).^[3]
TruBridge operating EBITDA is confirmed at $68mn annualised off the $300mn revenue base; combined IKS+TruBridge annualised revenue at close is ~$688mn.^[3]
Management identifies $575mn+ whitespace cross-sell opportunity within TruBridge's existing EHR client base for the IKS Care Enablement Platform, with immediate RCM whitespace of ~$440mn+.^[4]
TruBridge's COBOL-to-PostgreSQL EHR migration is expected to take ~18 - 24 months post-close and is a prerequisite for full agentic AI orchestration in TruBridge-native workflows.^[4]

AI and technology strategy

IKS is building proprietary small language models (SLMs) trained on 5mn+ de-identified patient records from TruBridge's database, targeting a hierarchical SLM+LLM architecture to reduce dependence on commercial foundational LLMs.^[3]
IKS acqui-hired ARAI for $1.2mn cash in Q4 FY26 to add knowledge-graph and neuro-symbolic (glass-box/explainable) AI capabilities to its platform.^[4]
Autonomous medical coding is being progressively expanded across additional medical specialties beyond the initial two; multi-agent orchestration for prior authorisation is also in deployment.^[6][5]

Expansion targets

True North target: combined IKS+TruBridge EBITDA to reach at least INR 3,000 crores by FY30, with net debt returning to pre-TruBridge levels (~INR 3,000mn) through internal cash generation and no further equity dilution beyond ESOPs.^[3][4]
Blended IKS+TruBridge EBITDA margin is expected to recover from ~26 - 27% post-consolidation to early-to-mid 30s within a couple of years, mirroring the AQuity integration trajectory.^[3][4]
IKS identifies ~50 enterprise customers with $50mn+ ACV potential over the next five years as primary wallet-expansion targets; converting 10 - 15 of these could add $500 - 750mn in incremental revenue.^[5]

Recent developments

TruBridge acquisition closed July 10, 2026, creating a ~$688mn combined revenue business; one-time integration/acquisition costs of ~INR 20cr were incurred in Q1 FY27 and a similar level is expected in Q2 FY27.^[3]
A major California health system signed as an Epic migration partner in Q1 FY27, validating the land-and-expand go-to-market strategy for large health systems.^[3]
An upfront NEVA guarantee payment of INR 1,430mn was made to a customer in Q1 FY27, suppressing reported free cash flow; FCF yield adjusted for this payment was 89.9%.^[3]
ESOP pool proposed to increase from 27,000,000 to 32,000,000 options, with benefits to be extended to employees of group companies, subsidiaries and associates in India and outside India.^[7]
No dividend was declared for FY 2025-26.^[7]

Market Cap

₹27,797 Cr

High / Low

₹1,969 / 1,262

Stock P/E

36.4

Price / Book

9.9

Book Value

₹163

EPS

₹42.1

No. of Shares

17.16 Cr

ROCE

31.8%

ROE

31.4%

OPM

30.7%

Debt / Equity

0.23

Sales

₹3,194 Cr

Net Profit

₹722 Cr

Promoter holding

63.7%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials